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Data set description: This data set is composed by label-free
alternate-scanning LC-MS/MS proteomics analysis human and
Wistar rat pancreatic islet endocrine cells.
The mass spectrometry data of the human and rat pancreatic beta
cells and the resulting proteome search output from ProteinLynx
GlobalSERVER (PLGS) have been deposited to the ProteomeXchange
Consortium [1] via the PRIDE partner repository with the dataset
identiﬁers PXD001539 (human) and PXD001816 (rat). From these
mass spectrometry data, ‘relative molar amount units’ between cell
types and across species were calculated.
Biological relevance: These data provide a quantitative view on
the unfractionated proteomes of human and rat beta and alpha cells.
It is likely biased towards the proteins with higher molar abundance,
relating to core functional pathways, but also includes several
proteins with an islet-enriched expression. The quality of the cell
preps is state-of-the-art, and the label-free quantitation is both
precise and accurate, allowing detailed quantitative analysis.
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).ier Inc. This is an open access article under the CC BY license
/j.jprot.2015.01.009
.A. Martens).
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subject areaRat and human pancreatic beta cell proteomicsType of data Excel tables
How data was
acquiredLabel-free alternate-scanning LC-MS proteomics; Nanoscale LC separation of tryptic peptides was
performed with
a nanoACQUITY system (Waters Corporation), equipped with a
Symmetry C18 5 mm, 2 cm 6180 mm precolumn and an Atlantis
C18 3 mm, 25 cm 675 mm or a Atlantis C18 3 mm, 15 cm
675 mm analytical reversed phase column (Waters Corporation).Data format Raw/Analyzed
Experimental factors Proteomes of rat alpha and beta cells were studied immediately after cell isolation, without in vitro
culture or treatment. Proteins were typically extracted within 4 h of animal killing. Human beta cells
were prepared from islet-enriched pancreas fractions, cultured for 6–14 days after human organ
procurement. Selected fractions cleared for research were then trypsin-dissociated into single cell
suspensions and FACS-sorted according to cell size, granularity and zinc content to an average
insulin-purity of 60%. Proteomes of these cells was studied immediately after cell isolation without
additional treatment or further culture.Experimental
featuresProteomes were recorded using label-free LC-MS/MS. Accurate mass precursor and fragment ion
LC-MS data were collected in data independent, alternate scanning (LC-MSE) mode of acquisition
[2,3]. Biological interpretation of the “relative molar amount units” was done after geometric
normalization to a network of stable reference proteins [4–8]Data source location Rat data: Waters Corp., Manchester, UK, Analyst: J.P.C. Vissers
Human data: Department of Medical Biochemistry, Academisch Medisch Centrum, Amsterdam,
the Netherlands, Analyst: G. KramerData accessibility Raw data uploaded to ProteomeXchange Consortium via the PRIDE partner repository with the
dataset identiﬁers
PXD001539: human data
Project DOI: 10.6019/PXD001539
Reviewer account details:
Username: reviewer99564@ebi.ac.uk
Password: pJzPiCIj
PXD001816: rat data
Project DOI: 10.6019/PXD001816
Username: reviewer43213@ebi.ac.uk
Password: y2B5bYLWValue of the data The methods for FACS-puriﬁcation of rat alpha and beta cells, and FACS-enrichment of human islet
endocrine cells were developed by our lab, and results in state-of-the-art endocrine purities. This
results in minimization of exocrine contamination, which is a problem affecting other proteomics
studies on these cell types Human and rat beta cells were analyzed using exactly the same methods of protein extraction,
trypsinization, LC-MS/MS analysis and downstream data analysis by the same people (Vissers and
Kramer). This makes it possible for the ﬁrst time to make a detailed quantitative comparison of the
core proteomes of this cell type in two species. We applied rigorous statistical criteria for peptide/protein identiﬁcation and quantiﬁcation,
thereby reducing false positive identiﬁcations perhaps at the expense of claimed coverage. We showed that alternate-scanning LC-MS/MS generated highly reproducible protein quantiﬁca-
tions (with overall technical plus biological imprecisiono20% and high accuracies as judged by
correct measurement of multi-enzyme stoichiometry [4]). A limitation is our depth of coverage: with an average of 400–500 protein identiﬁcations/
quantiﬁcations per cell type, our analysis is likely biased to the core proteome and proteins with
higher molar abundance.
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Description of the analyzed islet endocrine cell preparations:(i) FACS-puriﬁed rat insulin-producing beta cells (90% insulinþ , 3% glucagonþ , 1% somatostatinþ and
2% pancreatic polypeptideþ cells); n¼3 biological replicates, 3 technical replicate injections each:(ii) FACS-enriched rat glucagon-producing alpha cells (2% insulinþ , 94% glucagonþ , 1% somatostatinþ
and 2% pancreatic polypeptideþ cells); n¼3 biological replicates, 3 technical replicates each. Rat
alpha and beta cells were FACS-puriﬁed as described [9,10]. Cells were processed for proteomics
immediately after cell isolation without additional culture or treatment.(iii) FACS-enriched human beta cell preparations (n¼4 different donors, 3 technical replicates
each) and(iv) human pancreatic exocrine/duct cells (n¼1 biological replicate, 4 technical replicates). Human
beta cells were FACS-puriﬁed from pancreatic islet-enriched fractions that were prepared for
clinical islet transplantation in non-uremic type 1 diabetic patients. Sporadic cell preparations
not suitable for islet transplantation were cleared for research use. These cell preparations were
typically cultured for 6–14 days in HamF10 supplemented with 6 mM glucose, 2 mM glutamine,
0.5% BSA, penicillin/streptomycin, with refreshing of the medium and removal of dead cells every
3 days. Islet-enriched fractions were dissociated into single cell suspensions, and viable
endocrine cells FACS-isolated according to cell size, granularity and zinc content, to an average
insulin-positive purity of 6076% (range: 53–68%). These cells were then immediately processed
for proteomics, exactly as done for the rat cells, without further treatment or culture.Protein extraction After isolation, cell preparations were washed and soluble protein was extracted
with 0.5% (w/v) RapiGest detergent in 50 mM ammonium bicarbonate in the presence of Complete
Protease Inhibitor Cocktail and bovine DNAse II solution, followed by centrifugation to remove cellular
debris. One human beta cell pellet was subjected to an additional re-extraction in 1% (w/v) Rapigest to
verify if this resulted in higher recovery of hard-to-extract/membrane-bound proteins (HP2010,
Table 1). To remove protease inhibitors and most of reduced insulin molecules, protein extract was
reduced with 100 mM dithiothreitol (DTT). Proteins were denatured by heating at 80 1C for 15 min,
followed by 30 min at 60 1C after addition of 2.5 ml 100 mM DTT and another 30 min at ambient
temperature in the dark after addition of 2.5 ml 200 mM iodoacetamide. Trypsinization was carried
out overnight at 37 1C (1:25 w/w trypsin ratio) in ﬁnal volume of 100 ml. Finally, RapiGest detergent
was removed by acidifying digest to pH¼2 with triﬂuoroacetic acid and incubation for 15 min
at 37 1C.
LC-MS conﬁguration Nanoscale LC separation of the tryptic peptides was performed with a
NanoAcquity system (Waters Corporation). Samples were loaded on to a Symmetry C18 5 μm,
2 cm180 μm trap column (Waters) at a ﬂow rate of 5 μl/min prior to separation on a Bridged Ethyl
Hybrid C18 1.7 μm, 25 cm75 μm analytical reversed-phase column (Waters) by application of a
90 min gradient from 1% ACN and 0.1% formic acid to 40% ACN and 0.1% formic acid at a column ﬂow
rate of 0.25 μl/min. The column temperature was maintained at 35 1C. Analysis of the eluted tryptic
peptides was performed using a Synapt G2 Q-TOF (quadrupole time-of-ﬂight) mass spectrometer
(Waters Corporation) equipped with a nanolockspray source (Waters Corporation) ﬁtted with a
pico-tip emitter (New Objective) operated at a capillary voltage of approximately 3 kV. For all
measurements, the mass spectrometer was operated in v-mode with a typical resolution of at least
20,000 full width at half maximum. All analyses were performed in positive mode ESI. The time-of-
ﬂight analyzer of the mass spectrometer was externally calibrated with a NaI mixture from m/z 50 to
1990. The collision gas used was argon, maintained at a constant pressure of 2.0103 mbar in the
collision cell. The lock mass, [Glu1]-fFibrinopeptide B, was delivered from the auxiliary pump of the
NanoAcquity system with a concentration of 100 fmol/μl at 0.5 μl/min to the reference sprayer of the
nanolockspray source. The data were post-acquisition lock-mass corrected using the monoisotopic
mass of the doubly charged precursor of [Glu1]-Fibrinopeptide B, delivered through the reference
Table 1
Overview of all technical replicate LC-MS/MS injections of the indicated independent biological isolates. First column indicated
the sample name, second column listed the codes of individual technical replicates, as used in the supplementary raw MZml
data ﬁles.
Human pancreas number Code tech. Replicate % insulinþ % dead Rapigest
HP2010 3121 20111012_s4b human beta cells, donor 1 68 4 0.50%
20111103_s4a
20111103_s4c
HP2064 1421 20111103_s5a human beta cells, donor 2 62 3 0.50%
20111103_s5b
20111103_s5c
HP2785 2721 20111103_s6a human beta cells, donor 3 58 2 0.50%
20111103_s6b
20111103_s6c
HP2789 1821 20111103_s7a human beta cells, donor 4 53 4 0.50%
20111103_s7b
20111103_s7c
HP2703 2 20111103_s8a human duct/exocrine 2 24 0.50%
20111103_s8b
20111103_s8c
HP2010 3121 1% Rapigest 20111103_s16a re-extraction of HP2010 68 4 1.00%
20111103_s16b at 1% Rapigest
20111103_s16c (data not further used)
Rat beta cells Code tech. Replicate % insulinþ % glucagon Rapigest
beta 001 011108_002 biological replicate 1 90 3 0.50%
011108_003 (pool of 25 animals) (average)
011108_004
beta 002 011108_010 biological replicate 2
011108_011 (pool of 25 animals)
011108_012
beta 003 011108_019 biological replicate 3
011108_020 (pool of 25 animals)
011108_021
Rat alpha cells Code tech. Replicate % insulinþ % glucagon Rapigest
alpha 001 011108_006 biological replicate 1 2 94 0.50%
011108_007 (pool of 25 animals) (average)
011108_008 co-isolated with beta 001
alpha 002 011108_014 biological replicate 2
011108_015 (pool of 25 animals)
011108_016 co-isolated with beta 002
alpha 003 011108_022 biological replicate 3
011108_023 (pool of 25 animals)
011108_024 co-isolated with beta 003
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collected in data independent, alternate scanning (LC-MSE) mode of acquisition [2,3]
LC-MS data processing and protein identiﬁcation Continuum LC-MS data were processed and
searched using ProteinLynx GlobalSERVER v2.5 (Waters Corporation). Protein identiﬁcations were
obtained by searching databases of Rattus norvegicus databases (v15.12, 7449 entries) and Homo
Sapiens release (2011_11, 20,335 entries). Sequence information of Alcohol dehydrogenase
Saccharomyces cerevisiae was added to the databases to afford the ability to normalize the data
sets and to estimate amounts and concentration and that of known contaminant proteins (e.g. serum
albumin Bos taurus and trypsin Sus scrofa). A decoy was generated on the ﬂy with every database
search experiment conducted to estimate the protein false positive rate of identiﬁcation.
Data independent scanning protein identiﬁcations were accepted when more than three fragment
ions per peptide, seven fragment ions per protein and more than 2 peptides per protein were
Table 2
Overview of total proteins identiﬁed and quantiﬁed by LC-MS/MS in the various cell preparations, along criteria speciﬁed in
Materials & Methods.
rat human
beta alpha beta exocrine
number of proteins identiﬁed nZ1 506 417 462 372
number of proteins quantiﬁed nZ2 465 353 413 300
GEO-normalized molar amount highest 3.61 8.22 8.95 14.74
lowest 0.02 0.02 0.01 0.06
dynamic range 226 548 746 246
biological replicates (x) 3 3 4 1
technical replicates (n) 3 3 3 3
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the protein was detected in at least 2 out of 3 technical replicate of at least one biological replicate.
Typical search criteria used for protein identiﬁcation included automatic peptide and fragment ion
tolerance settings (approximately 10 and 25 ppm, respectively), 1 allowed missed cleavage, ﬁxed
carbamidomethyl-cysteine modiﬁcation and variable methionine oxidation. Raw data were expressed
as ‘relative molar amount units’ calculated by dividing the determined molar amount for a given
protein by the summed determined amount for all identiﬁed proteins as this accounts for both
technical and biological variations [3,4,11]. To enable reuse of the continuum LC-MS data by other
proteome search engines, MS1 and reconstructed MSn mass spectrometric data generated by PLGS
were exported in mzML format.
Geometric normalization between cell types and across species: to compare these relative molar
amounts between cell types and across species, data were biologically interpreted after geometric
normalization to a set of stable housekeeping proteins, as described in the associated 4 Pubmed-
indexed studies thus far: analysis of the rat beta cell proteome [4], identiﬁcation of doublecortin [5],
protein phosphatase 1-inhibitor 1 [6] and ubiquitin thioesterase-L1 [8] as candidate real-time
biomarkers for beta cell destruction (Table 2).Acknowledgment
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